Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage

Abstract Background KRAS mutations frequently occur in cancers, particularly pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer. Although KRAS G12C inhibitors have recently been approved, effective precision therapies have not yet been established for all KRAS-mutant...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Hiroshi Kotani, Hiroko Oshima, Justin C. Boucher, Tomoyoshi Yamano, Hiroyuki Sakaguchi, Shigeki Sato, Koji Fukuda, Akihiro Nishiyama, Kaname Yamashita, Koushiro Ohtsubo, Shinji Takeuchi, Takumi Nishiuchi, Masanobu Oshima, Marco L. Davila, Seiji Yano
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	BMC 2024-07-01
Sarja:	Journal of Biomedical Science
Aiheet:	KRAS MYC SUMOylation MEK DNA damage
Linkit:	https://doi.org/10.1186/s12929-024-01060-3
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!